SEARCH

SEARCH BY CITATION

References

  • 1
    Frishman WH. Alpha- and beta-adrenergic blocking drugs. In: FrishmanWH, SonnenblickEH, SicaDA, eds. Cardiovascular Pharmacotherapeutics. 2nd ed. New York, NY: McGraw Hill; 2003:6797.
  • 2
    Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948;153:586599.
  • 3
    Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: HardmanJG, LimbirdLE, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York, NY: McGraw Hill; 2001.
  • 4
    Brodde OE, Bruck H, Leineweber K. Cardiac adrenoreceptors: physiological and pathophysiological relevance. J Pharmacol Sci. 2006;100:323337.
  • 5
    Black JW, Stephenson JS. Pharmacology of a new adrenergic beta-receptor blocking compound (nethalide). Lancet. 1962;2:311314.
  • 6
    Powell CE, Slater IH. Blocking of inhibitory adrenergic receptors by a dichloro analog of isoproterenol. J Pharmacol Exp Ther. 1958;122:480488.
  • 7
    Black JW, Crowther AF, Shanks RG, et al. A new adrenergic beta receptor antagonist. Lancet. 1964;13:10801081.
  • 8
    Alcock SJ, Bond PA. Observations of the toxicity of alderlin (pronethalol) in laboratory animals. Proc Eur Soc Study Drug Toxicity. 1964;4:3039.
  • 9
    Stephen SA. Unwanted effects of propranolol. Am J Cardiol. 1966;18:463468.
  • 10
    Frishman WH. Clinical Pharmacology of the Beta- Adrenoreceptor Blocking Drugs. 2nd ed. Norwalk, CT: Appleton-Century-Crofts; 1984.
  • 11
    Lands AM, Arnold A, McAuliff JP, et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature. 1967;214:597598.
  • 12
    Koch-Weser J. Drug therapy: metoprolol. N Engl J Med. 1979;301:698703.
  • 13
    Wright P. Untoward effect associated with practolol administration: oculomucocutaneous syndrome. BMJ. 1975;1:595598.
  • 14
    Koch-Weser J, Frishman WH. β-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981;305:500506.
  • 15
    Frishman WH. Drug therapy. Pindolol: a new β-adrenoceptor antagonist with partial agonist activity. N Engl J Med. 1983;308:940944.
  • 16
    Frishman WH. Clinical differences between beta-adrenergic blocking agents: implications for therapeutic substitution. Am Heart J. 1987;113:11901198.
  • 17
    Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:16.
  • 18
    Frishman W, Halprin S. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part VII: new horizons in beta-adrenoceptor blocking therapy: labetalol. Am Heart J. 1979;98:660665.
  • 19
    Frishman WH, Sica DA. β-Adrenergic blockers. In: IzzoJL, Jr, SicaD, BlackHR, eds. Hypertension Primer. 4th ed. Dallas, TX: American Heart Association. In press.
  • 20
    Frishman WH. Carvedilol. N Engl J Med. 1998;339:17591765.
  • 21
    Frishman WH, Lazar EJ, Gorodokin G. Pharmacokinetic optimization of therapy with beta-adrenergic blocking agents. Clin Pharmacokinet. 1991;20:311318.
  • 22
    Frishman WH. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1: pharmacokinetic and pharmacodynamic properties. Am Heart J. 1979;97:663670.
  • 23
    Toprol XL [package insert]. Wilmington DE: AstraZeneca; 2006.
  • 24
    Coreg CR (carvedilol phosphate) extended-release capsules [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2007.
  • 25
    Frishman WH. Atenolol and timolol, two new systemic adrenoceptor antagonists. N Engl J Med. 1982;306:14561462.
  • 26
    Frishman WH. Nadolol: a new β-adrenoceptor antagonist. N Engl J Med. 1981;305:678684.
  • 27
    Frishman WH, Furberg CD, Friedewald WT. β-Adrenergic blockade for survivors of acute myocardial infarction. N Engl J Med. 1984;310:830837.
  • 28
    Murthy VS, Frishman WH. Controlled beta receptor blockade with esmolol and flestolol. Pharmacotherapy. 1988;8:168182.
  • 29
    Sung RJ, Blanski L, Kirschenbaum J, et al. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia. J Clin Pharmacol. 1986(suppl A):A15A26.
  • 30
    Ward SA, Walle T, Walle UK, et al. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin Pharmacol Ther. 1989;45:7279.
  • 31
    COSOPT (dorzolamide/timolol) [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2003.
  • 32
    Hamer J, Grandjean T, Melendez L, et al. Effect of propranolol (Inderal) in angina pectoris: preliminary report. BMJ. 1964;2:720723.
  • 33
    Frishman WH. Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease. Circulation. 1983;67(6 pt 2):I11I18.
  • 34
    Inderide (propranolol hydrochloride and hydrochlorothiazide) tablet [package insert]. Madison, NJ: Wyeth Pharmaceuticals Inc; 2006.
  • 35
    Atenolol [package insert]. Corona, CA: Watson Pharmaceuticals; 2006.
  • 36
    Corzide (nadolol and bendroflumethiazide) tablet [package insert]. Bristol, TN: Monarch Pharmaceuticals, Inc; 2006.
  • 37
    Frishman WH, Cavusoglu E. β-Adrenergic blockers and their role in the therapy of arrhythmias. In: PodridPJ, KoweyPR, eds. Cardiac Arrhythmias: Mechanisms, Diagnosis and Management. Baltimore, MD: Williams &Wilkins; 1995:421433.
  • 38
    Esmolol [package insert]. Bedford, OH: Ben Venue Laboratories, Inc; 2004.
  • 39
    Sotalol [package insert]. Montville, NJ: Berlex Laboratories; 2004.
  • 40
    Cavusoglu E, Frishman WH. Sotalol: a new β-adrenergic blocker for ventricular arrhythmias. Prog Cardiovasc Dis.1995;37:423440.
  • 41
    Prichard BN. Hypotensive action of pronethalol. BMJ. 1964;1:12271228.
  • 42
    Prichard BN, Gillam PMS. Use of propranolol (Inderal) in the treatment of hypertension. BMJ. 1964;2:725727.
  • 43
    The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Institutes of Health. NIH Publication No. 98–4080, November 1997.
  • 44
    Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:16841689.
  • 45
    Bakris GL, Fonseca V, Katholi RE, et al, for the GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:22272236.
  • 46
    Braunwald E. Treatment of the patient after myocardial infarction. The last decade and the next. N Engl J Med. 1980;302:290293.
  • 47
    MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomised placebo-controlled international trial. Eur Heart J. 1985;6:199226.
  • 48
    Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: multicentre study of metoprolol in survivors of acute myocardial infarction. Eur Heart J. 1987;8:10561064.
  • 49
    Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357:13851390.
  • 50
    Engelmeier RS, O'Connell JB, Walsh R, et al. Improvement in symptoms and exercise tolerance by metoprolol in patients with dilated cardiomyopathy: a double-blind, randomized, placebo-controlled trial. Circulation. 1985;72:536546.
  • 51
    LeJemtel TH, Sonnenblick EH, Frishman WH. Diagnosis and management of heart failure. In: FusterV, AlexanderRW, O'RourkeRA, et al, eds. Hurst's The Heart. 11th ed. New York, NY: McGraw Hill; 2004:723762.
  • 52
    Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:16591667.
  • 53
    Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215225.
  • 54
    Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade. Circulation. 1967;35:847851.
  • 55
    Winkle RA, Lopes MG, Goodman DS, et al. Propranolol for patients with mitral valve prolapse. Am Heart J. 1977;93:422427.
  • 56
    Dorostkar PC, Eldar M, Belhassen B, et al. Long-term follow up of patients with long QT syndrome treated with ß blockers and continuous pacing. Circulation. 1999;100:24312436.
  • 57
    Kornbluth A, Frishman WH, Ackerman B. Beta-adrenergic blockade in children. Cardiol Clin. 1987;5:629649.
  • 58
    Slater EE, DeSanctis RW. Dissection of the aorta. Med Clin North Am. 1979;63:141154.
  • 59
    Rios AS, Silber EN, Bavishi N, et al. Effect of long-term β-blockade on aortic root compliance in patients with Marfan syndrome. Am Heart J. 1999;137:10571061.
  • 60
    Frishman WH, Razin A, Swencionis C, et al. Beta-adrenoceptor blockade in anxiety states: a new approach to therapy. Update. Cardiovasc Rev Rep. 1992;13:813.
  • 61
    Auerbach AD, Goldman L. β-Blockers and reduction of cardiac events in noncardiac surgery. Clinical applications. JAMA. 2002;287:14451447.
  • 62
    Weber RB, Reinmuth OM. The treatment of migraine with propranolol. Neurology. 1972;22:366369.
  • 63
    Young RR, Growdon JH, Shahani BT. Beta-adrenergic mechanisms in action tremor. N Engl J Med. 1975;293:950953.
  • 64
    Frishman WH, Kowalski M, Nagnur S, et al. Cardiovascular considerations in using topical, oral and intravenous drugs for the treatment of glaucoma and ocular hypertension. Focus on β-adrenergic blockade. Heart Dis. 2001;3:386397.
  • 65
    Kraus ML, Gottlieb LD, Horwitz RI, et al. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med. 1985;313:905909.
  • 66
    Frishman WH, Clark A, Johnson B. Effects of cardiovascular drugs on plasma lipids and lipoproteins. In: FrishmanWH, SonnenblickEH, eds. Cardiovascular Pharmacotherapeutics. New York, NY: McGraw Hill; 1997:15151559.
  • 67
    Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201207.
  • 68
    Oka Y, Frishman W, Becker RM, et al. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 10. Beta-adrenoceptor blockade and coronary artery surgery. Clinical pharmacology. Am Heart J. 1980;99:255269.
  • 69
    Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol. 1987;59:26F32F.